Identifying high-risk combinations of metformin during COVID-19
PLOS One · 04.03.2026 · 21 (3) · e0343979
DOI: 10.1371/journal.pone.0343979 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 04.03.2026. Verfasst von Jelena Dimnjaković und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department for Biostatistics, Division for Health Informatics and Biostatistics, Croatian Institute of Public Health, Zagreb, Croatia. Hauptthemen laut MEDLINE: Metformin, Hypoglycemic Agents, COVID-19 Drug Treatment, COVID-19. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
There is a lack of research addressing associations of antidiabetic drug combinations with COVID-19 deaths. We examined whether adding common second-line agents to metformin was associated with COVID-19 mortality risk to inform clinical decision-making when escalating diabetes treatment.
Methods
This is a nationwide retrospective analysis covering the years 2020 and 2021. Data from the National Diabetes Registry (CroDiab) were linked to primary healthcare data, Causes of Death Registry data, and the SARS-CoV-2 vaccination database. Multivariate logistic regression models were developed for each of the combinations to compare the combination with metformin monotherapy. To address confounders, inverse probability of treatment weighting (IPTW) analysis as well as analysis with stabilized weights was performed.
Results
Of 141014 analyzed patients, 1268 (0.90%) died of COVID-19 in 2 years. Weighted results of the drug combinations that showed statistically significant associations to COVID-19 death in comparison to metformin alone were metformin+DPP-4 inhibitor (OR 1.182, 95% CI 1.016–1.376), metformin+sulfonylurea (OR 1.195, 95% CI 1.015–1.406), and metformin+GLP-1 agonist (OR 2.992, 95% CI 2.117–4.229).
Conclusions
Some combinations of metformin with second-line antidiabetic drugs might require caution in the context of chronic diabetes mellitus type 2 therapy and COVID-19 related deaths. Findings should be interpreted as hypothesis-generating signals from real-world data rather than evidence of causal drug effects. Further research is needed, especially for metformin+GLP-1 agonist, as well as head-to-head comparisons of combinations therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department for Biostatistics, Division for Health Informatics and Biostatistics, Croatian Institute of Public Health, Zagreb, Croatia.
- Health center "Dom zdravlja Zagreb zapad", Zagreb, Croatia.
- Department of Environmental and Occupational Health and Sports Medicine, School of Medicine, University of Zagreb, Zagreb, Croatia.
- Department of Social Medicine and Organization of Health Care, School of Medicine, University of Zagreb, Zagreb, Croatia.
ORCID-Profile: Tamara Poljičanin, Hana Brborović, Emanuel Brađašević
Zitieren
APA
Dimnjaković, J., Buble, T., Poljičanin, T., Brborović, H., Brađašević, E., & Brborović, O. (2026). Identifying high-risk combinations of metformin during COVID-19. PLOS One, 21(3), e0343979. https://doi.org/10.1371/journal.pone.0343979
Vancouver
Dimnjaković J, Buble T, Poljičanin T, Brborović H, Brađašević E, Brborović O. Identifying high-risk combinations of metformin during COVID-19. PLOS One. 2026;21(3):e0343979. doi:10.1371/journal.pone.0343979
BibTeX
@article{Dimnjakovi2026,
author = {Dimnjaković, Jelena and Buble, Tamara and Poljičanin, Tamara and Brborović, Hana and Brađašević, Emanuel and Brborović, Ognjen},
title = {Identifying high-risk combinations of metformin during COVID-19},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0343979},
doi = {10.1371/journal.pone.0343979}
}
EUVIMED